Literature DB >> 17889173

Recurrence of hepatocellular carcinoma after liver transplantation.

A Escartin1, G Sapisochin, I Bilbao, R Vilallonga, J Bueno, L Castells, C Dopazo, E Castro, M Caralt, J Balsells.   

Abstract

Outcome after liver transplantation (OLT) clearly depends on recurrence of hepatocellular carcinoma (HCC). After recurrence, patient outcome will depend on the time and site of appearance. The aim of this study was to analyze the therapeutic implications of tumor recurrence behavior. From October 1988 to December 2005, 685 patients received OLT, including 202 due to HCC (32%). We analyzed 28 recurrences (15.2%) among 184 patients who survived at least 3 months (minimum follow-up 1 year). According to the time of recurrence, we divided the patients into early recurrence (ER < 12 months; n = 9; 32.1%) and late recurrence (LR > 12 months n = 19; 67.9%). Actuarial survivals at 1, 5, and 10 years were 82%, 65%, and 50% and disease-free survival, 80%, 58%, and 46%, respectively. Risk factors for recurrence were: vascular invasion (P < .01), bad differentiation (P < .01), and previous hepatectomy (P < .05). After OLT, ER presented at: 5.7 +/- 2.3 months (range 3-10) vs 33.5 +/- 24.3 months (range 12-103) for LR P < .001). Survival postrecurrence (SPR) was shorter: 3.1 +/- 2.4 (range 1-8) months vs 16.4 +/- 14.2 (range 1-5) months (P < .001). Treatment was offered to one ER (11%) and to eight LR (47.1%; P < .05), achieving in these cases longer SPR: 20.1 +/- 14 vs 6.9 +/- 9 months (P < .05). The most common sites of recurrence were liver (n = 7), lung (n = 7), bone (n = 5), adrenal gland (n = 2), peritoneum (n = 2), lymph node (n = 2), skin (n = 2) or cerebral (n = 1). Early recurrences showed short survivals; no treatment could be offered to these patients. Liver recurrence appeared early. In contrast, most lung recurrences appeared later with the possibility of treatment and longer SPR. Bone recurrence appeared later, usually associated with other locations. Treatment was palliative and prognosis was worse. Skin and lymph node recurrences can be treated curatively with prolonged survival. In conclusion, HCC recurrence was difficult to treat curatively and was only prevented by employing restricted criteria.

Entities:  

Mesh:

Year:  2007        PMID: 17889173     DOI: 10.1016/j.transproceed.2007.06.042

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  27 in total

Review 1.  Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review.

Authors:  Nicola de'Angelis; Filippo Landi; Maria Clotilde Carra; Daniel Azoulay
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

2.  Validity of eleven prognostic scores with respect to intra- and extrahepatic recurrence of hepatocellular carcinoma after liver transplantation.

Authors:  A Bauschke; A Altendorf-Hofmann; H Kissler; A Koch; C Malessa; U Settmacher
Journal:  J Cancer Res Clin Oncol       Date:  2017-08-28       Impact factor: 4.553

3.  Pre-operative Microvascular Invasion Prediction Using Multi-parametric Liver MRI Radiomics.

Authors:  Giacomo Nebbia; Qian Zhang; Dooman Arefan; Xinxiang Zhao; Shandong Wu
Journal:  J Digit Imaging       Date:  2020-12       Impact factor: 4.056

4.  Solitary extrahepatic intraabdominal metastasis from hepatocellular carcinoma after liver transplantation.

Authors:  Sae Byeol Choi; Hyungi Kim; Sung Hoon Kim; Young Nyun Park; Kyung Sik Kim
Journal:  Yonsei Med J       Date:  2011-01       Impact factor: 2.759

Review 5.  Therapies for hepatocellular carcinoma: overview, clinical indications, and comparative outcome evaluation-part one: curative intention.

Authors:  Joseph H Yacoub; Christine C Hsu; Thomas M Fishbein; David Mauro; Andrew Moon; Aiwu R He; Mustafa R Bashir; Lauren M B Burke
Journal:  Abdom Radiol (NY)       Date:  2021-04-09

6.  Surgery for Hepatocellular Carcinoma in Patients with Child-Pugh B Cirrhosis: Hepatic Resection Versus Living Donor Liver Transplantation.

Authors:  Norifumi Harimoto; Tomoharu Yoshizumi; Yukiko Fujimoto; Takashi Motomura; Youhei Mano; Takeo Toshima; Shinji Itoh; Noboru Harada; Toru Ikegami; Hideaki Uchiyama; Yuji Soejima; Yoshihiko Maehara
Journal:  World J Surg       Date:  2018-08       Impact factor: 3.352

7.  Late recurrence of hepatocellular carcinoma after liver transplantation.

Authors:  Julia A Zhang; Sandi A Kwee; Linda L Wong
Journal:  Hepatoma Res       Date:  2017-04-10

8.  [Diagnosis of and therapy for hepatocellular carcinoma].

Authors:  T F Greten; N P Malek; S Schmidt; J Arends; P Bartenstein; W Bechstein; T Bernatik; M Bitzer; A Chavan; M Dollinger; D Domagk; O Drognitz; M Düx; S Farkas; G Folprecht; P Galle; M Geißler; G Gerken; D Habermehl; T Helmberger; K Herfarth; R T Hoffmann; M Holtmann; P Huppert; T Jakobs; M Keller; J Klempnauer; F Kolligs; J Körber; H Lang; F Lehner; F Lordick; A Lubienski; M P Manns; A Mahnken; M Möhler; C Mönch; P Neuhaus; C Niederau; M Ocker; G Otto; P Pereira; G Pott; J Riemer; K Ringe; U Ritterbusch; E Rummeny; P Schirmacher; H J Schlitt; K Schlottmann; V Schmitz; A Schuler; H Schulze-Bergkamen; D von Schweinitz; D Seehofer; H Sitter; C P Straßburg; C Stroszczynski; D Strobel; A Tannapfel; J Trojan; I van Thiel; A Vogel; F Wacker; H Wedemeyer; H Wege; A Weinmann; C Wittekind; B Wörmann; C J Zech
Journal:  Z Gastroenterol       Date:  2013-11-15       Impact factor: 2.000

9.  Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus (HCV) Liver Transplant Recipients Treated with Pretransplant Direct-Acting Antiviral (DAA) Therapy.

Authors:  Nicholas Lim; Dupinder Singh; Scott Jackson; John R Lake
Journal:  Gastrointest Tumors       Date:  2020-09-14

10.  Risk factors for poor survival after recurrence of hepatocellular carcinoma after liver transplantation.

Authors:  Minjeong Kim; Jinsoo Rhu; Gyu-Seong Choi; Jong Man Kim; Jae-Won Joh
Journal:  Ann Surg Treat Res       Date:  2021-06-30       Impact factor: 1.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.